Inhibrx logo
Inhibrx logo

Inhibrx

inhibrx.com
inhibrx.com • HQ: La Jolla, United States • Venture - Series Unknown 2023 • 1001-5000 employees • Founded 2017 • Startup • New
HQ: La Jolla, United States • Venture - Series Unknown 2023 • 1001-5000 employees • Founded 2017 • Startup • New
Actively hiring
Biotechnology
Follow
Overview
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Total raised
$668.6M
5 rounds on record
Latest round
$200M
Venture round · Aug 2023 · 3 yr ago
Team
1001-5000
employees, estimated range
Backers
1
LAV
The money's age
Long since its last round
36 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 31, 2023 Raised a round Venture round $200M · SEC Form D Apr 6, 2020 Raised a round Venture round $15M · SEC Form D May 20, 2019 Raised a round Venture round $40M · SEC Form D May 4, 2018 Raised a round Venture round $3.6M · SEC Form D Apr 30, 2018 Raised a round Venture round $410M · SEC Form D 2017 Founded
Funding rounds
RoundDateAmountInvestorsSource
Venture round Aug 2023 $200M — SEC Form D
Venture round Apr 2020 $15M — SEC Form D
Venture round May 2019 $40M — SEC Form D
Venture round May 2018 $3.6M — SEC Form D
Venture round Apr 2018 $410M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Inhibrx, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Brendan EckelmanExecutive OfficerSEC Form D
Mark LappeExecutive Officer, DirectorSEC Form D
Kelly DeckExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
LAV fund
Similar startupsby what they do, their industry and backers
Caravel Bio
We reinvented protein engineering.. [email protected].
Protillion Biosciences11-50 employees • 1 role
Explore Therapeutic Protein Libraries. For decades, therapeutic antibody discovery and optimization has been a shot in the Dark With the…
Lyell51-200 employees • 8 roles
Learn about Lyell and how we are building an industry-leading clinical-stage pipeline of CAR-T cell product candidates for cancer.
Ordaos, Inc.Venture round $338k · 19 mo ago • Founded 2019 • 51-200 employees
Human-enabled Machine-driven. De novo designed mini-proteins and single domain antibodies to help drug hunters deliver life-saving…
Saudi Aramco
At Aramco, our behavior is what defines us - as a company, as employees, as people. Everything we do is anchored by our corporate values…
Kisoji Biotechnology Inc.11-50 employees
KisoJi Biotechnology. Breakthrough antibody discovery forbreakthrough therapeutics.

Overview

Anchored by our protein-engineering expertise and our proprietary single-domain antibody platform, we’ve developed a unique pipeline of therapeutic candidates.

People

Brendan Eckelman
Executive Officer
SEC Form D
Mark Lappe
Executive Officer, Director
SEC Form D
Kelly Deck
Executive Officer
SEC Form D
Jon Kayyem
Director
SEC Form D
Margery Fischbein
Director
SEC Form D
Judith Li
Director
SEC Form D
Doug Forsyth
Director
SEC Form D
Kristiina Vuori
Director
SEC Form D
Kimberly Manhard
Director
SEC Form D
Douglas Forsyth
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
La Jolla United States
HQ
Contact Us
1000-5000 est. staff
11025 N Torrey Pines Rd #140, La Jolla, CA 92037
company site

Financials

Total raised
$668.6M
Latest round
Venture - Series Unknown
Funding rounds
5
Funding rounds
Round Announced Amount
Venture - Series Unknown 2023 $200M Details
Venture - Series Unknown 2020 $15M Details
Venture - Series Unknown 2019 $40M Details
Venture - Series Unknown 2018 $3.6M Details
Venture - Series Unknown 2018 $410M Details